openPR Logo
Press release

Opioid-Induced Constipation (OIC) Treatment Market Analysis By Active Ingredients, By Method of Administration with IMP Key Players - GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals,

11-20-2018 01:20 PM CET | Health & Medicine

Press release from: Future Market Insights

Opioid-Induced Constipation (OIC) Treatment Market Analysis

Opioids are a class of medications that are regularly endorsed for their pain relieving, or pain-killing, properties it is chronic and non-cancer pain. A typical symptom connected with the utilization of these medications are that they decrease the gastrointestinal tract's motility, making solid discharges and making patients strain. In addition, prolonged utilization of opioids can prompt the harm of sensory system that causes body cells to quit creating endogenous opioids, for example, endorphins.

There is high risk of constipation in adults since they have poor diet, poor fluid intake and immobility. The typical symptoms for opioid-induced constipation are feeling lethargic, hard and dry stools, distention and bulged abdomen, painful defecation and loss of appetite. The opioid-induced constipation (OIC) treatment market is an exceptionally alluring and promising market because of the expanding base of opioid-induced constipation OIC sufferers.

Opioid-Induced Constipation (OIC) Treatment Market: Drivers and Restraints

Raising base of the illegal medication users and delayed utilization of opioids in the treatment of chronic pain are the essential elements energizing the development of the opioid- induced constipation (OIC) treatment business sector. In addition, expanded mindfulness among patients and doctors for utilizing non-purgative medicine choices to treat opioid induced constipation would promote drive the development of the OIC treatment market sooner rather than later.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1245

In addition, it has been assessed that the undiscovered market for successful, advantageous and safe medication treatment in OIC drug is profoundly broad and developing. However, lack of awareness about opioid-induced constipation in patients, absence of mindfulness with respect to the forthcoming treatment innovation, high costs of novel pharmaceuticals and unfavorable reimbursement guidelines by medical coverage organizations are probably the most prevailing limit for the opioid- induced constipation treatment market.

Opioid-Induced Constipation (OIC) Treatment Market: Overview

With expanding base of opioid-induced constipation (OIC) sufferers, the opioid-induced constipation (OIC) treatment market is expected to have tremendous growth during the forecast period (2016-2026). The latest trend in the opioid-induced constipation market is development of novel and effective treatment technology by incurring nominal expenses in research and development (R&D). Introducing convenient dosing, peripherally restricted μ-opioid receptor antagonist (PAMORA) target main cause of opioid- induced constipation (OIC) thiswill drive the opioid- induced constipation (OIC) treatment market.

Opioid-Induced Constipation (OIC) Treatment Market: Segmentation

Globalopioid-induced constipation (OIC)marketis segmented on the basis of active ingredients, administration of drugs, drug class, distribution channel and geography as following:

Segmentation by Active Ingredients

Naloxegol

Lubiprostone

Methylnaltrexone Bromide

Docusate Sodium

Others (Osmotic laxatives, Emollient or lubricant cathartics, Bulk cathartics, Stimulant cathartics, Prostaglandins or prokinetic drugs)

Segmentation by method of administration

Oral

Parenteral (Subcutaneous Injection)

Segmentation by drug class

Peripherally-Restricted μ-opioid Receptor Antagonist (PAMORA)

Non-selective opioid antagonist

μ-Opioid antagonist

Locally Acting Chloride Channel Activator (LACCA)

Segmentation by Distribution Channel

Drug store

Independent Pharmacies

Hospital Pharmacies

Opioid-Induced Constipation (OIC) Treatment Market: Region- wise Outlook

North America is the main market for opioid induced constipation treatment because of the expanding base of OIC sufferers and illegal medication users. It is then followed by Europe because of high incidence of opioid-induced constipation OIC for chronic pain. Besides that, Latin America and South East-Asia area are some of potential areas where presentation of successful opioid-induced constipation treatments may help up the general income of a specific pharmaceutical organization, because of the expanding base of OIC sufferers.

The high development of the opioid-induced constipation market is credited to the strong government motivation in healthcare sector likewise with the vicinity of an extensive pool of patients suffering from chronic pain

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-1245

Opioid-Induced Constipation (OIC) Treatment Market: Key Players

Key Players operating in this segment are GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited

ABOUT US:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Opioid-Induced Constipation (OIC) Treatment Market Analysis By Active Ingredients, By Method of Administration with IMP Key Players - GlaxoSmithKline, Inc., AstraZeneca plc, Inc., Pfizer, Inc., S.L.A. Pharma AG, AIKO Biotechnology, Cubist Pharmaceuticals, here

News-ID: 1385568 • Views:

More Releases from Future Market Insights

Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
The Anesthesia Equipment Market is witnessing robust growth, with its value estimated at USD 9.3 billion in 2025 and projected to nearly double to USD 18.2 billion by 2035. This growth trajectory represents a compound annual growth rate of 7.0%, driven by increasing surgical volumes, rising prevalence of chronic respiratory and cardiovascular disorders, and ongoing expansion of healthcare infrastructure. The market is undergoing transformative change, as both established manufacturers and
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
The intravascular ultrasound (IVUS) systems market is on track to record consistent growth over the next decade. Valued at USD 893.7 million in 2025, the market is expected to expand to USD 1455.7 million by 2035, reflecting a compound annual growth rate of 5.0%. With cardiovascular disease remaining one of the leading causes of mortality globally, the demand for advanced intravascular imaging technologies is escalating. IVUS systems, which provide real-time
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
The global Electric Power Sports Market is on a fast track to transformation, as consumers, manufacturers, and policymakers align on one powerful goal: sustainable, high-performance recreational experiences. Valued at USD 10.3 billion in 2025, the market is projected to expand to USD 18.5 billion by 2035, reflecting a steady compound annual growth rate (CAGR) of 6.0%. This momentum is set to generate an absolute dollar opportunity of USD 8.2 billion over
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovation and Consumer Demand Drive Growth
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovatio …
The global hair straightener market is entering a transformative growth phase, as industry leaders and emerging brands alike innovate to meet rising consumer demand for advanced hair styling solutions. Valued at USD 7.1 billion in 2025, the market is projected to reach USD 12.4 billion by 2035, registering a compound annual growth rate (CAGR) of 5.7% over the forecast period. Between 2025 and 2030, the market is set to rise steadily

All 5 Releases


More Releases for OIC

Opioid-Induced Constipation (OIC) Drug Market Will Generate Record Revenue by 20 …
Opioid-Induced Constipation (OIC) Drug Market is anticipated to grow at a significant CAGR during the forecast period. The major factor that is expected to boost the market growth includes rising number of geriatric patients as these patients use opioid analgesics such as morphine, hydromorphone, codeine, etc. as a prescription for chronic non-cancer pain which has severe adverse effects on the digestive system resulting in huge demand for OIC drugs. For
Targeted Treatment Options For Opioid-Induced Constipation (OIC) In Global Marke …
Opioids are prescription drugs taken for treatment of chronic pain. While they relieve the pain, they can give opioid-induced constipation. The adverse effects associated with the opioids are decreasing gastrointestinal tract’s motility, making patient’s strain, and making of solid discharges. Adults are most likely to prone to opioid-induced constipation owing to less immobility, poor diet, and fluid intake. The opioid-induced constipation treatment market is growing at a significant rate owing
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018 - Research By Marke …
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape. Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its
Opioid-Induced Constipation (OIC) - Complete Analysis on Therapeutics by Stage o …
A new research document is added in HTF MI database of 64 pages, latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2018, provides an overview of the Opioid-Induced Constipation (OIC) (Toxicology) pipeline landscape. Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes
Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017, provides an overview of the Opioid-Induced Constipation (OIC) (Oncology) pipeline landscape. Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect
Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016
Global Markets Directs, Opioid-Induced Constipation (OIC) - Pipeline Review, H2 2016, provides an overview of the Opioid-Induced Constipation (OIC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development